Identifying biomarkers for lung cancer immunotherapy
Official title: Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
Run by Samsung Medical Center · NCT03578185 · Data updated 2026-11-12
This study is trying to find specific markers in lung cancer patients' samples to see if they can predict how well immunotherapy treatments will work for them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | immunotherapy, chemotherapy, radiation |
| Locations | 3 sites (Seoul, Gangnam-gu and 2 other locations) |
| Status | Recruiting |
| Started | April 11, 2018 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | August 12, 2026 |
| Trial ID | NCT03578185 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with histologically confirmed lung cancer who have been treated with immune checkpoint inhibitors.
✕Probably not a fit
Patients who have not been treated with immune checkpoint inhibitors or those under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify predictive biomarkers for immunotherapy in lung cancer patients by analyzing samples such as tumor tissue, blood, and fecal material from individuals treated with immune checkpoint inhibitors. The study will collect clinical data, including demographics, treatment history, and histologic information, to correlate with the biomarker findings. Informed consent is waived for samples donated from other clinical trials, allowing for a broader analysis of existing data.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective immunotherapy treatments for lung cancer patients.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for immunotherapy, suggesting that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. aged above or equal to 18 2. Histologically confirmed lung cancer patients 3. Patient treated with immune checkpoint inhibitor Exculsion Criteria: NA
Where it's running
-
Samsung Medical Center
Seoul, Gangnam-gu, South Korea Recruiting -
Seoul National University Hospital
Seoul, Joungro-gu, South Korea Recruiting -
Asan Medical Center
Seoul, Songpa-gu, South Korea Not yet recruiting
Study contacts
- Study coordinator: Se-hoon Lee, MD
- Email: sehoon.lee@samsung.com
- Phone: +82-10-4759-7640
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.